摘要
多发性硬化症(MS)是一种复杂、致残的慢性神经系统疾病,全球MS患者超过210万。从1993年首个专门治疗RRMS药物获得美国FDA批准上市以来,全球已陆续批准12个疾病修饰药物(DMAs)上市。医疗专业人员需判断药物收益风险比,以确定每个患者的最佳治疗方案。本文综述了已上市的多发性硬化症的治疗药物,为临床用药提供参考。
Multiple sclerosis （MS） is a complex, chronic, and often disabling neurological disease, and MS affects more than 2.1 million people worldwide. Since the first MS drug was approved by the U. S. Food and Drug Administration （FDA） specially to treat RRMS in 1993, 12 approved DMAs emerged from years in the world. Health care professionals should evaluate cost-effectiveness of the therapies to determine the treatment option that best fits the needs and preferences of individual patients.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2014年第23期2748-2752,共5页
Chinese Journal of New Drugs
